# Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

> **NCT00020969** · PHASE2 · TERMINATED · sponsor: **CTI BioPharma**

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **DRUG:** arsenic trioxide

## Key facts

- **NCT ID:** NCT00020969
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-03
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** — (—)
- **Last updated:** 2020-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00020969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00020969, "Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00020969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*